The Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 Years
Latest Information Update: 06 Apr 2022
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 28 Mar 2022 Status changed from active, no longer recruiting to completed.
- 01 Oct 2020 New trial record